Publications by authors named "Inge Kemper"

Claim this Profile
M
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
Anna van der Voort, Fleur M Louis, Mette S van Ramshorst, Rob Kessels, Ingrid A Mandjes, Inge Kemper

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
Leonie Voorwerk, Olga I Isaeva, Hugo M Horlings, Sara Balduzzi, Maksim Chelushkin, Inge Kemper

Nat Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
Anna van der Voort, Mette S van Ramshorst, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper

JAMA Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk, Maarten Slagter, Hugo M Horlings, Karolina Sikorska, Koen K van de Vijver, Inge Kemper

Nat Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk, Maarten Slagter, Hugo M Horlings, Karolina Sikorska, Koen K van de Vijver, Inge Kemper

Nat Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
Mette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Mette S van Ramshorst, Erik van Werkhoven, Aafke H Honkoop, Vincent O Dezentjé, Irma M Oving, Inge Kemper

Breast· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis